Natural Killer Cell Regulation of B Cell Responses in the Context of Viral Infection

Gyurova, Ivayla E; Ali, Ayad; Waggoner, Stephen N.

doi:10.1089/vim.2019.0129

Cited by 25 publications

(17 citation statements)

References 122 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…27 Together these data suggest that concerted immune responses that may include the help of cytokine producing NK cells yield the best antibody concentrations after vaccination. 27,28 Almost 50% of patients did not reach S1 IgG 300 BAU/ml. Many of these patients nevertheless demonstrated a clear increase in antibody concentrations after each vaccination, suggesting that antibody responses can be further enhanced with one or more extra vaccinations.…”

Section: Discussionmentioning

confidence: 97%

Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients

Haggenburg¹,

Lissenberg‐Witte

Binnendijk

et al. 2022

Blood Advances

View full text Add to dashboard Cite

Vaccination guidelines for patients treated for hematological diseases are typically conservative. Given their high risk for severe coronavirus infectious disease 2019 (COVID-19) it is important to identify those patients that benefit from vaccination. We prospectively quantified serum IgG antibodies to spike subunit 1 (S1) antigens during and after 2-dose mRNA-1273 (Spikevax/Moderna) vaccination in hematology patients. Obtaining S1 IgG ≥300 binding antibody units (BAU)/ml was considered adequate as it represents the lower level of S1 IgG concentration obtained in healthy individuals and it correlates with potent virus neutralization. Selected patients (n=723) were severely immunocompromised due to their disease or treatment thereof. Nevertheless, more than 50% of patients obtained S1 IgG ≥300 BAU/ml after 2-dose mRNA-1273. All patients with sickle cell disease or chronic myeloid leukemia obtained adequate antibody concentrations. Around 70% of patients with chronic graft versus host disease (GvHD), multiple myeloma, or untreated chronic lymphocytic leukemia (CLL) obtained S1 IgG ≥300 BAU/ml. Ruxolitinib or hypomethylating therapy but not high-dose chemotherapy blunted responses in myeloid malignancies. Responses in lymphoma patients, CLL patients on ibrutinib, and chimeric antigen receptor T cell recipients were low. The minimal time-interval after autologous hematopoietic cell transplantation (HCT) to reach adequate concentrations was <2 months for multiple myeloma, 8 months for lymphoma, and 4-6 months after allogeneic HCT. Serum IgG4, absolute B and NK cell number and number of immunosuppressants predicted S1 IgG ≥300 BAU/ml. Hematology patients on chemotherapy, shortly after HCT, or with chronic GvHD should not be precluded from vaccination. Netherlands Trial Register NL9553.

show abstract

Section: Discussionmentioning

confidence: 97%

Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients

Haggenburg¹,

Lissenberg‐Witte

Binnendijk

et al. 2022

Blood Advances

View full text Add to dashboard Cite

show abstract

“… 2018 ; Gyurova et al. 2020 ). Age or immune system diseases make subjects more prone to develop viral infections, as in over 60 years of age patients, B and T lymphocytes formation is reduced.…”

Section: Pathophysiology Of Covid -19mentioning

confidence: 99%

In quest of a new therapeutic approach in COVID-19: the endocannabinoid system

Lucaciu

Aghiorghiesei

Petrescu

et al. 2021

Drug Metabolism Reviews

View full text Add to dashboard Cite

The SARS-Cov-2 virus caused a high morbidity and mortality rate disease, that is the COVID-19 pandemic. Despite the unprecedented research interest in this field, the lack of specific treatments leads to severe complications in a high number of cases. Current treatment includes antivirals, corticosteroids, immunoglobulins, antimalarials, interleukin-6 inhibitors, anti-GM-CSF, convalescent plasma, immunotherapy, antibiotics, circulation support, oxygen therapy, and circulation support. Due to the limited results, until specific treatments are available, other therapeutic approaches need to be considered. The endocannabinoid system is found in multiple systems within the human body, including the immune system. Its activation can lead to beneficial results such as decreased viral entry, decreased viral replication, and a decrease in pro-inflammatory cytokines such as IL-2, IL-4, IL-6, IL-12, TNF-α, or IFN-γ. Moreover, endocannabinoid system activation can lead to an increase in anti-inflammatory cytokines, mainly represented by IL-10. Overall, the cannabinoid system can potentially reduce pulmonary inflammation, increase the immunomodulatory effect, decrease PMN infiltration, reduce fibrosis, and decrease viral replication, as well as decrease the ‘cytokine storm’. Although the cannabinoid system has many mechanisms to provide certain benefits in the treatment of SARS-CoV-2 infected patients, research in this field is needed for a better understanding of the cannabinoid impact in this situation.

show abstract

“…A significant increase in NK cells has been found to occur in the early stage of primary infection, in congenital infected neonates and in transplant recipients [33]. Activated NK cells produce proinflammatory cytokines (e.g., TNF-α and IFN-γ) and cytotoxic granules containing effector molecules (e.g., granzyme B and perforin) to cause the lysis or apoptosis of infected cells [34]. NK cells also directly kill transformed and infected cells via antibody-dependent cellular cytotoxicity (ADCC) [35,36].…”

Section: Innate Immune Responsesmentioning

confidence: 99%

microRNA, a Subtle Indicator of Human Cytomegalovirus against Host Immune Cells

Jin

Zhang

et al. 2022

Vaccines

View full text Add to dashboard Cite

Human cytomegalovirus (HCMV) is a double-stranded DNA virus that belongs to the β-herpesvirus family and infects 40–90% of the adult population worldwide. HCMV infection is usually asymptomatic in healthy individuals but causes serious problems in immunocompromised people. We restricted this narrative review (PubMed, January 2022) to demonstrate the interaction and molecular mechanisms between the virus and host immune cells with a focus on HCMV-encoded miRNAs. We found a series of HCMV-encoded miRNAs (e.g., miR-UL112 and miR-UL148D) are explicitly involved in the regulation of viral DNA replication, immune evasion, as well as host cell fate. MiRNA-targeted therapies have been explored for the treatment of atherosclerosis, cardiovascular disease, cancer, diabetes, and hepatitis C virus infection. It is feasible to develop an alternative vaccine to restart peripheral immunity or to inhibit HCMV activity, which may contribute to the antiviral intervention for serious HCMV-related diseases.

show abstract

Natural Killer Cell Regulation of B Cell Responses in the Context of Viral Infection

Cited by 25 publications

References 122 publications

Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients

Quantitative analysis of mRNA-1273 COVID-19 vaccination response in immunocompromised adult hematology patients

In quest of a new therapeutic approach in COVID-19: the endocannabinoid system

microRNA, a Subtle Indicator of Human Cytomegalovirus against Host Immune Cells

Contact Info

Product

Resources

About